文献速递前列腺癌

使用DROP-IN伽马探针的机器人辅助前列腺特异性膜抗原放射引导挽救性手术治疗复发性前列腺癌:首个前瞻性可行性研究

Robot-assisted Prostate-specific Membrane Antigen-radioguided Salvage Surgery in Recurrent Prostate Cancer Using a DROP-IN Gamma Probe: The First Prospective Feasibility Study.
PubMed 文献 · Eur Urol · 2022-03-24

这项前瞻性可行性研究纳入20例既往根治性治疗后PSMA PET显示最多三个盆腔复发灶的前列腺癌患者,评估微型DROP-IN伽马探针能否将PSMA放射引导手术转化至机器人手术。结果显示19/21(90%)PSMA avid病灶可经机器人切除,病灶水平敏感度86%、特异度100%,术后12/18(67%)患者PSA下降>50%,4/18(22%)达完全生化反应,随访至15个月4/18(22%)无生化复发,1例发生Clavien-Dindo >III级并发症。

要点

  • DROP-IN探针使机器人辅助PSMA放射引导手术在复发性前列腺癌中技术可行。
  • 19/21(90%)PSMA avid病灶可经机器人切除,病灶水平敏感度86%、特异度100%。
  • 12/18(67%)患者PSA下降>50%,4/18(22%)达PSA<0.2 ng/ml,1例Clavien-Dindo >III级并发症。

核心结论

  • DROP-IN探针有助于实现机器人辅助PSMA放射引导手术,该操作在术中检测淋巴结或局部PSMA avid前列腺癌复发灶方面技术可行。

研究设计与样本

  • 前瞻性可行性研究,纳入20例既往根治性治疗后分期PSMA PET显示最多三个盆腔前列腺癌复发灶(淋巴结或局部)的患者。
  • 机器人辅助PSMA放射引导手术在静脉注射99mTc-PSMA-I&S后19-23小时进行。

主要发现

  • 使用DROP-IN探针,19/21(90%)PSMA avid病灶可经机器人切除。
  • 病灶水平机器人辅助PSMA放射引导手术的敏感度为86%,特异度为100%。
  • 12/18(67%)患者PSA下降>50%,4/18(22%)患者达完全生化反应(PSA<0.2 ng/ml)。
  • 随访至15个月,4/18(22%)患者保持无生化复发(PSA≤0.2 ng/ml)。
  • 1例患者发生Clavien-Dindo >III级并发症。

关键数值与推荐

  • 主要终点为机器人辅助PSMA放射引导手术的可行性。
  • 次要终点包括切除标本放射性状态与最终组织病理学结果的比较、PSMA放射引导手术后的PSA反应、按Clavien-Dindo分类的并发症。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It has been proven that intraoperative prostate-specific membrane antigen (PSMA)-targeted radioguidance is valuable for the detection of prostate cancer (PCa) lesions during open surgery. Rapid extension of robot-assisted, minimally invasive surgery has increased the need to make PSMA-radioguided surgery (RGS) robot-compliant. OBJECTIVE: To evaluate whether the miniaturized DROP-IN gamma probe facilitates translation of PSMA-RGS to robotic surgery in men with recurrent PCa. DESIGN, SETTING, AND PARTICIPANTS: This prospective feasibility study included 20 patients with up to three pelvic PCa recurrences (nodal or local) on staging PSMA positron emission tomography (PET) after previous curative-intent therapy. SURGICAL PROCEDURE: Robot-assisted PSMA-RGS using the DROP-IN gamma probe was carried out 19-23 h after intravenous injection of 99mtechnetium PSMA-Investigation & Surgery (99mTc-PSMA-I&S). MEASUREMENTS: The primary endpoint was the feasibility of robot-assisted PSMA-RGS. Secondary endpoints were a comparison of the radioactive status (positive or negative) of resected specimens and final histopathology results, prostate-specific antigen (PSA) response following PSMA-RGS, and complications according to the Clavien-Dindo classification. RESULTS AND LIMITATIONS: Using the DROP-IN probe, 19/21 (90%) PSMA-avid lesions could be resected robotically. On a per-lesion basis, the sensitivity and specificity of robot-assisted PSMA-RGS was 86% and 100%, respectively. A prostate-specific antigen (PSA) reduction of >50% and a complete biochemical response (PSA <0.2 ng/ml) were seen in 12/18 (67%) and 4/18 (22%) patients, respectively. During follow-up of up to 15 mo, 4/18 patients (22%) remained free of biochemical recurrence (PSA ≤0.2 ng/ml). One patient suffered from a Clavien-Dindo grade >III complication. CONCLUSIONS: The DROP-IN probe helps in realizing robot-assisted PSMA-RGS. The procedure is technically feasible for intraoperative detection of nodal or local PSMA-avid PCa recurrences. PATIENT SUMMARY: A device called the DROP-IN probe facilitates minimally invasive, robot-assisted surgery guided by radioactive tracers in patients with recurrent prostate cancer. This procedure holds promise for improving the intraoperative identification and removal of prostate cancer lesions.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. de Barros HA, van Oosterom MN, Donswijk ML, et al. Robot-assisted Prostate-specific Membrane Antigen-radioguided Salvage Surgery in Recurrent Prostate Cancer Using a DROP-IN Gamma Probe: The First Prospective Feasibility Study. Eur Urol. 2022. PMID: 35339318. doi:10.1016/j.eururo.2022.03.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。